Thrivent Financial for Lutherans
GALT icon

Thrivent Financial for Lutherans’s Galectin Therapeutics GALT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,727
Closed -$57K – 2213
2019
Q2 		$57K Sell
13,727
-1,451
-10% -$6.28K ﹤0.01% 2176
2019
Q1 		$78K Buy
+15,178
New +$72.9K ﹤0.01% 2142
2017
Q4 		– Sell
-6,000
Closed -$13K – 2126
2017
Q3 		$13K Buy
+6,000
New +$11.9K ﹤0.01% 2120

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Thrivent Financial for Lutherans's GALT Position: Q3 2019 in Review

Thrivent Financial for Lutherans sold out of Galectin Therapeutics (GALT) in Q3 2019, closing a stake of 13,727 shares — an estimated $57K sold.

Thrivent Financial for Lutherans first reported a position in GALT in Q3 2017 and held it in 3 quarters. The position peaked at $78K in Q1 2019. 80 funds tracked by Wall St. Rank hold GALT as of Q3 2019.

  • Thrivent Financial for Lutherans reported no remaining Galectin Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 13,727 Galectin Therapeutics shares in Q3 2019, an estimated $57K.
  • Thrivent Financial for Lutherans first reported a position in Galectin Therapeutics in Q3 2017 and held it in 3 quarters.
  • Thrivent Financial for Lutherans's Galectin Therapeutics position peaked at $78K in Q1 2019.
  • 80 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2019.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2019, filed 14 Nov 2019.